Code Bio is a cutting-edge biotech startup that is revolutionizing the field of genetic medicine. The company is developing a new class of precision genetic medicines to treat life-threatening diseases. Their proprietary technology, 3DNA®, is a synthetic DNA delivery platform that has been designed to overcome the numerous challenges associated with the delivery of genetic medicines. These challenges include dose-related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, the ability to re-dose, and vector manufacturing complexity.

Code Bio's business model revolves around the development and commercialization of their 3DNA® platform and the genetic medicines it enables. The company is currently advancing an internal pipeline focusing on a variety of diseases, with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). They also have research programs underway targeting the lungs, pancreas, and liver.

The company's target market includes patients suffering from life-threatening diseases that can be treated with genetic medicines. Code Bio also seeks partnerships with other entities to further develop and commercialize their strategic programs that hold promise for genetic diseases.

In terms of revenue generation, Code Bio likely makes money through the licensing of its 3DNA® platform, partnerships with other biotech and pharmaceutical companies, and potentially, the sale of its genetic medicines once they receive regulatory approval.

Keywords: Genetic Medicine, Biotech Startup, 3DNA® Platform, Disease Treatment, Duchenne’s Muscular Dystrophy, Synthetic DNA Delivery, Life-threatening Diseases, Bioavailability, Cell Specific Targeting, Strategic Partnerships.